Baclofen reduces excessive nerve signals that make muscles stiff or spasm. It is prescribed for adults with skeletal muscle spasticity linked to multiple sclerosis, spinal cord injury, or brain disease.
Baclofen is a centrally acting skeletal muscle relaxant. By activating GABA-B receptors in the central nervous system, it can ease abnormal muscle tone and support movement.
Baclofen is a centrally acting skeletal muscle relaxant. Its main clinical use is the treatment of persistent muscle spasticity, where muscles remain tight, overactive, or resistant to movement because nerve pathways are damaged.
Spasticity differs from an occasional muscle cramp. A cramp is usually brief and localised. Spasticity may continue for weeks or months, affect several muscle groups, interfere with walking, disturb sleep, and make dressing or personal care difficult.
Doctors may prescribe Baclofen when increased muscle tone is associated with:
The treatment goal is not to remove every muscle contraction. Some muscle tone can help a person stand or transfer safely. Prescribers therefore adjust treatment to reduce troublesome stiffness while preserving useful strength. The UK Summary of Product Characteristics describes Baclofen as a treatment for spasticity arising from conditions affecting the brain or spinal cord [1].
Baclofen acts mainly as a GABA-B receptor agonist. GABA is a chemical messenger that reduces excessive nerve activity. GABA-B receptors are found in the spinal cord and brain, including nerve pathways involved in muscle reflexes.
After Baclofen activates these receptors, signals travelling through spinal reflex circuits become less intense. The medicine reduces both monosynaptic and polysynaptic reflex activity:
This action does not numb the muscles or directly repair the underlying neurological disease. It changes how strongly abnormal nerve signals reach the muscles. The result may be less spasm, reduced resistance during movement, and improved comfort during physiotherapy.
Baclofen can also affect the brain. That explains unwanted effects such as drowsiness, slowed reactions, dizziness, and reduced alertness. The degree of sedation depends on the individual response, the dose, kidney function, other medicines, and alcohol exposure. The EMA pharmacological assessment describes Baclofen’s activity through GABA-B receptors in the central nervous system [2].
Baclofen is not suitable for everyone. This treatment is not for you if you have had a serious allergic reaction to Baclofen or any tablet ingredient.
Baclofen may be unsuitable or require specialist supervision if you have:
Baclofen may intensify the effects of opioids, benzodiazepines, sedating antihistamines, sleep medicines, and other central nervous system depressants. Alcohol can add to drowsiness, impaired coordination, and breathing suppression.
People taking antihypertensive medicines may experience more pronounced blood-pressure lowering. Medicines that affect kidney function may also alter Baclofen exposure. A prescriber needs a complete list of medicines, including non-prescription sedatives and recreational substances, before treatment begins.
Abrupt withdrawal can cause serious symptoms, including anxiety, hallucinations, agitation, delirium, seizures, increased spasticity, fever, and muscle breakdown. Regular treatment should be reduced gradually under clinical direction rather than stopped suddenly.
This treatment is not for you if you have had a serious allergic reaction to Baclofen or any tablet ingredient. Talk to a clinician before using it if you have severe kidney problems, breathing weakness, epilepsy, a stomach ulcer, significant mental-health problems, pregnancy or breastfeeding, or severe muscle weakness.
Baclofen may not be suitable if you take opioids, benzodiazepines, sedating antihistamines, sleeping medicines, or other medicines that slow the nervous system. Alcohol can make drowsiness, poor coordination, and breathing problems worse.
Baclofen can cause unwanted effects because it suppresses excessive nerve activity in the spinal cord and also produces central nervous system effects. Drowsiness, dizziness, sedation, fatigue, weakness, nausea, and headache are recognised reactions.
The likelihood of side effects may rise after a dose increase, when treatment starts, or when Baclofen is combined with another sedating substance. Some reactions improve as the body adjusts. Persistent or severe symptoms need prompt clinical review.
A useful distinction is between expected mild sleepiness and dangerous reduced consciousness. Mild sleepiness can still make driving unsafe. Extreme difficulty waking, slow or shallow breathing, collapse, or blue-tinged lips requires emergency assistance.
Large amounts, accidental double dosing, impaired kidney clearance, or combinations with other central nervous system depressants may produce:
Respiratory depression means breathing becomes too slow or too shallow to maintain normal oxygen and carbon dioxide levels. It is a medical emergency, especially when Baclofen is combined with opioids, sedatives, sleeping tablets, or alcohol.
Baclofen is a centrally acting skeletal muscle relaxant. It activates GABA-B receptors in the central nervous system and helps reduce excessive nerve signals associated with muscle stiffness and spasms.
Baclofen tablets are taken by mouth. The amount and frequency depend on the purpose of use and are agreed with a doctor or pharmacist.
The amount of Baclofen used and how often it is taken depend on the condition being treated and are agreed with a doctor or pharmacist. Treatment commonly begins cautiously, followed by gradual adjustment according to muscle response and tolerability.
Key administration principles include:
Gradual dose adjustment helps identify the lowest amount that controls spasticity without causing excessive weakness or sedation. A person who becomes unusually sleepy, confused, unsteady, or weak may require a review of treatment.
Kidney function deserves attention because Baclofen is cleared largely through the kidneys. Older adults and people with reduced renal function can be more sensitive to central nervous system effects. The MHRA safety information describes serious toxicity, including confusion, reduced consciousness, and respiratory depression, when Baclofen accumulates or is taken in excessive amounts [3].
Baclofen is selected when spasticity arises from neurological disease and spinal reflex activity needs to be reduced. Other medicines act through different pathways, so the preferred option depends on the pattern of stiffness, muscle weakness, sleepiness, liver or kidney function, and other treatment goals.
| Medicine or category | Main mechanism and clinical distinction | Common limitations |
|---|---|---|
| Baclofen | GABA-B receptor agonist; used mainly for neurological spasticity | Drowsiness, weakness, dizziness, withdrawal risk |
| Tizanidine | Alpha-2 adrenergic agonist that reduces excitatory motor signals | Sedation, low blood pressure, dry mouth, liver monitoring |
| Diazepam | Enhances GABA-A activity; reduces muscle activity and anxiety | Sedation, dependence, impaired coordination, withdrawal risk |
Tizanidine may be considered when a shorter-acting treatment is useful or when Baclofen is poorly tolerated. Diazepam can reduce muscle spasm but carries dependence and sedation concerns, making prolonged use unsuitable for many people. Pregabalin works through calcium-channel modulation and may be chosen when neuropathic pain is also present, although it is not a direct substitute for Baclofen’s action on GABA-B receptors.
Baclofen is intended mainly for neurological spasticity, not every episode of acute muscular discomfort. A new back pain episode, leg cramp, or isolated strain may have a different cause and may not respond appropriately.
In clinical practice, doctors often judge Baclofen by function rather than by the complete disappearance of spasms. Better sleep, easier stretching, fewer painful spasms, and safer transfers can represent meaningful benefit even when some stiffness remains.
Prescribers usually prefer gradual changes. A sudden increase may reduce tone quickly but leave the person too weak or sleepy to walk safely. A gradual plan allows the clinician to identify whether a lower amount provides enough relief.
Renal function is an important part of prescribing. Older adults and people with chronic kidney disease may develop toxicity at amounts tolerated by younger adults with normal renal clearance. The British National Formulary and MHRA safety communications both emphasise caution with central nervous system depression and withdrawal.
Baclofen can cause drowsiness, dizziness, reduced coordination, blurred vision, and slower reactions. These effects may affect driving, cycling, working at height, and operating machinery, especially after treatment starts or the amount changes. The MHRA safety information published in 2014 advises caution with medicines that impair alertness and coordination. Do not drive until your individual response is clear. The risk may increase with alcohol or other sedating medicines.
Older adults may be more sensitive to sedation, confusion, dizziness, and muscle weakness. Reduced kidney function can allow Baclofen to accumulate, increasing the risk of toxicity. NICE guidance published in 2015 supports careful medication review in older people who are vulnerable to falls or central nervous system effects. A clinician may use slower adjustment and closer monitoring in this group.
Sudden withdrawal after regular use can cause rebound spasticity, agitation, confusion, hallucinations, fever, seizures, and, in severe cases, muscle breakdown or organ complications. The EMA product information published in 2018 identifies abrupt withdrawal as a serious risk requiring urgent attention. A prescriber normally reduces regular treatment gradually, with the pace depending on the duration of use, the amount taken, and the underlying neurological condition.
A confirmed serious allergy to Baclofen or one of its ingredients rules out treatment. Severe kidney impairment may also make oral Baclofen unsuitable or require specialist prescribing because accumulation can cause coma or respiratory depression. The MHRA renal-safety advice published in 2014 highlights the need for careful assessment in people with impaired kidney function. A history of severe Baclofen toxicity is another clear reason to avoid re-exposure.
The duration depends on whether spasticity is temporary, progressive, or associated with a long-term neurological condition. Some people use Baclofen for months or years when it continues to improve function and remains tolerable. The British National Formulary reviewed in 2025 describes continued treatment as requiring regular assessment of benefit, weakness, sedation, and withdrawal risk. Long-term use should be reviewed rather than continued automatically.
Alcohol can increase Baclofen-related sleepiness, poor coordination, confusion, and respiratory depression. The WHO alcohol guidance published in 2022 supports avoiding combinations that add central nervous system depression. The risk is higher with opioids, benzodiazepines, sleeping tablets, or other sedatives. Avoid alcohol until a prescriber has assessed the combination and you know how Baclofen affects you.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Brighton, had taken Baclofen for several weeks after multiple-sclerosis-related leg spasms. He reported fewer night-time jerks and easier stretching, although the first few days brought noticeable drowsiness.
Southampton, said Baclofen had reduced painful stiffness after a spinal injury. He had initially taken a dose before work and felt too slow to concentrate, so his clinician changed the timing.
Cardiff, had used the tablets for persistent lower-limb spasticity. He described better sleep after the first month, but still experienced weakness when the amount was increased.
Edinburgh, reported limited benefit for sudden back pain and stopped after feeling dizzy. His experience reflected the difference between acute muscular pain and neurological spasticity.
Stoke-on-Trent, had found Baclofen useful for spasms linked to a spinal condition. He had missed several doses and developed marked stiffness, which improved after a supervised return to regular treatment.
